Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study.
Clinical phenotype
Continuous positive airway pressure
Refractory hypertension
Resistant hypertension
Journal
Hypertension research : official journal of the Japanese Society of Hypertension
ISSN: 1348-4214
Titre abrégé: Hypertens Res
Pays: England
ID NLM: 9307690
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
26
02
2019
accepted:
15
05
2019
revised:
26
04
2019
pubmed:
19
6
2019
medline:
9
10
2020
entrez:
19
6
2019
Statut:
ppublish
Résumé
Refractory hypertension (RfH) is defined as a lack of blood pressure control despite the administration of at least 5 anti-hypertensive drugs. The factors associated with its natural history are unknown. This study aimed to evaluate both the incidence of RfH in an cohort of patients with resistant hypertension (RH) and the factors involved in that progression. This was an observational prospective multicenter study (24 centers) with 172 patients with confirmed RH (24-h ABPM) who underwent a further 24 h ABPM study at the end of the follow-up. Prospective information was obtained from all patients in their corresponding Hypertension Units via a standard clinical protocol, and they all underwent a sleep study. Thirty patients were diagnosed with RfH (17.4%) after a mean follow-up of 57 months, despite the prescription of a greater number of long-acting thiazide-like diuretics and mineralocorticoid receptor antagonists. The factors associated with progression to RfH were: a longer period since the diagnosis of RH (OR: 1.06, 95% CI: 1.01-1.1, p = 0.007); the HbA1c concentration (OR: 1.42, 95% CI: 1.42-1.8; p = 0.005); the initial heart rate (OR: 1.05, 95% CI: 1.01-1.09, p = 0.004); and poor adherence to continuous positive airway pressure (CPAP) in cases of obstructive sleep apnea (OR: 3.36, 95% CI: 1.47-7.7, p = 0.004). In conclusion, a considerable percentage of patients evolved from the RH to the RfH phenotype despite changes in their treatment. Some easily measurable variables, such as heart rate, the time since the diagnosis, the HbA1c level, and the presence of untreated obstructive sleep apnea (or poor adherence to CPAP) have been demonstrated to be prognostic factors in the progression to RfH.
Identifiants
pubmed: 31209397
doi: 10.1038/s41440-019-0285-8
pii: 10.1038/s41440-019-0285-8
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1708-1715Références
Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am J Respir Crit Care Med. 2010;182:598–604.
doi: 10.1164/rccm.200912-1843CC
pubmed: 20522794
Agusti A, Celli B, Faner R. What does endotyping mean for treatment in chronic obstructive pulmonary disease? Lancet. 2017;390:980–7.
doi: 10.1016/S0140-6736(17)32136-0
pubmed: 28872030
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the management of arterial hypertension. J Hypertens. 2018;2018(36):2284–309.
doi: 10.1097/HJH.0000000000001961
Spence JD, Rayner BL. Hypertension in Blacks: individualized therapy based on renin/aldosterone phenotyping. Hypertension. 2018;72:263–9.
doi: 10.1161/HYPERTENSIONAHA.118.11064
pubmed: 29941519
Mirzababaei A, Mozaffari H, Shab-Bidar S, Milajerdi A, Djafarian K Risk of hypertension among different metabolic phenotypes: a systematic review and meta-analysis of prospective cohort studies. J Hum Hypertens. 2018. https://doi.org/10.1038/s41371-018-0146-y.
doi: 10.1038/s41371-018-0146-y
pubmed: 30568291
Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226–32.
doi: 10.1161/HYPERTENSIONAHA.109.129882
pubmed: 19564548
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation and treatment: a scientific statement from the American Heart Association professional education committee of the council for high blood pressure research. Hypertension. 2008;51:1403–19.
doi: 10.1161/HYPERTENSIONAHA.108.189141
pubmed: 18391085
Gaddam K, Nishizaka M, Pratt-Ubunama M, Pimenta E, Aban I, Oparil S, et al. Resistant hypertension characterized by increased aldosterone levels and persistent intravascular volume expansion. Arch Intern Med. 2008;168:1159–64.
doi: 10.1001/archinte.168.11.1159
pubmed: 18541823
pmcid: 2748247
Junqueira CLC, Magalhães MEC, Brandão AA, Ferreira E, FZGA Cyrino, Maranhão PA, et al. Microcirculation and biomarkers in patients with resistant or mild-to-moderate hypertension: a cross-sectional study. Hypertens Res. 2018;41:515–23.
doi: 10.1038/s41440-018-0043-3
pubmed: 29686318
Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Crowley K, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis; REACH Registry Investigators. Eur Heart J. 2013;34:1204–14.
doi: 10.1093/eurheartj/ehs368
pubmed: 23144048
Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18:1422–8.
doi: 10.1016/j.amjhyper.2005.05.014
pubmed: 16280275
Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and non-resistant hypertension. Kidney Int. 2015;88:622–32.
doi: 10.1038/ki.2015.142
pubmed: 25945406
pmcid: 4556588
Persell SD. Epidemiology/population studies prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57:1076–80.
doi: 10.1161/HYPERTENSIONAHA.111.170308
pubmed: 21502568
Egan BM, Zaho Y, Axon RN, Brezinsky WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988–2008. Circulation. 2011;124:1046–58.
doi: 10.1161/CIRCULATIONAHA.111.030189
pubmed: 21824920
pmcid: 3210066
de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension clasified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898–902.
doi: 10.1161/HYPERTENSIONAHA.110.168948
pubmed: 21444835
Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: a novel phenotype of antihypertensive treatment failure. Hypertension. 2016;67:1085–92.
doi: 10.1161/HYPERTENSIONAHA.116.06587
pubmed: 27091893
pmcid: 5425297
Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66:126–33.
doi: 10.1161/HYPERTENSIONAHA.115.05449
pubmed: 25987662
pmcid: 4465856
Martínez-García MA, Capote F, Campos-Rodríguez F, Lloberes P, Díaz de Atauri MJ, Somoza M, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension. The HIPARCO randomized clinical trial. J Am Med Assoc. 2013;310:2407–15.
doi: 10.1001/jama.2013.281250
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.
doi: 10.1097/01.hjh.0000431740.32696.cc
O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–68.
doi: 10.1097/HJH.0b013e328363e964
pubmed: 24029863
Martínez-García MA, Navarro-Soriano C, Torres G, Barbé F, Caballero-Eraso C, Lloberes P, et al. Beyond resistant hypertension. Relationship between refractory hypertension and obstructive sleep apnea. Hypertension. 2018;72:618–24.
doi: 10.1161/HYPERTENSIONAHA.118.11170
pubmed: 30354751
Navarro-Soriano C, Martinez-Garcia MA, Torres G, Barbé F, Caballero C, Lloberes P, et al. Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea. A post-hoc intention-to-treat analysis of the HIPARCO randomized clinical trial. J Hypertens. 2019. https://doi.org/10.1097/HJH.0000000000002053 .
doi: 10.1097/HJH.0000000000002053
pubmed: 30676482
Armario P, Calhoun DA, Oliveras A, Blanch P, Vinyoles E, Banega JR, et al. Prevalence and clinical characteristics of refractory hypertension. J Am Heart Assoc. 2017;6:e007365. https://doi.org/10.1161/JAHA.117.007365
doi: 10.1161/JAHA.117.007365
pubmed: 29217663
pmcid: 5779046
Calhoun DA, Booth JN III, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension . 2014;63:451–8.
doi: 10.1161/HYPERTENSIONAHA.113.02026
pubmed: 24324035
Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108:3097–101.
doi: 10.1161/01.CIR.0000103123.66264.FE
pubmed: 14676139
Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;23(114):1804–14.
doi: 10.1161/CIRCRESAHA.114.302524
Persu A, O´Brien E, Verdecchia P. Use of ambulatory Blood pressure measurement in the definition of resistant hypertension. A review of the evidence. Hypertens Res. 2014;37:967–72.
doi: 10.1038/hr.2014.83
pubmed: 24739542
Acelajado MC, Pisoni R, Dudenbostel T, Dell’Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens. 2012;14:7–12.
doi: 10.1111/j.1751-7176.2011.00556.x
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. ACC /AHA /AAPA /ABC /ACPM /AGS /APhA /ASH /ASPC /NMA /PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension . 2018;71(6):e13–e115.
pubmed: 29133356